Nasdaq

Tonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer Models

Tonix Pharmaceuticals has published a study demonstrating that the combination of mTNX-1700, a fusion protein targeting neutrophil-mediated immune evasion, with an anti-PD1 antibody significantly ...
ascopubs.org

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). This ...
Nasdaq

Tonix Pharmaceuticals Reports Promising Preclinical Data for TNX-1700 Combining TFF2 with Anti-PD1 Antibody in Cancer Therapy

Tonix Pharmaceuticals presented promising data on TNX-1700 for gastric and colorectal cancers, enhancing anti-PD1 therapy effectiveness in preclinical models. Tonix Pharmaceuticals has announced ...
ascopubs.org

Rectal arterial infusion chemotherapy combined with anti-PD1 antibody for microsatellite stable locally advanced rectal cancer: The effectiveness and safety of a single-arm ...

A phase II study of short-course radiotherapy followed by sintilimab, anlotinib combined with CAPOX as neoadjuvant treatment for locally advanced MSS/pMMR rectal cancer (ZZU-1 study). This is an ASCO ...
Seeking Alpha

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with ...
News Tribune

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today ...
GEN

Immunotherapy Response May Be Influenced by Patient’s Own Autoantibodies

A landmark study headed by researchers at Yale School of Medicine and at Fred Hutchinson Cancer Center has revealed that autoantibodies (AAbs)—immune proteins traditionally associated with autoimmune ...